查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822370

2032 年败血症治疗抗生素市场预测：依药物类别、病原体类型、给药途径、通路、应用、最终用户和地区进行分析

Septicemia Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Pathogen Type, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球用于治疗败血症的抗生素市场预计在 2025 年达到 27.3 亿美元，到 2032 年将达到 38.2 亿美元，预测期内的复合年增长率为 4.9%。

用于治疗败血症的抗生素是控制血液细菌感染的重要处方药。败血症，通常被称为血液中毒，如果不紧急治疗，可能会迅速致命。这些抗生素透过破坏或抑制细菌生长发挥作用，有助于预防器官损伤和全身併发症。根据感染源的不同，治疗方案包括频谱或特异性病原体的抗生素，以确保有效控制病情。使用这些抗生素对于降低与败血症相关的死亡率至关重要。

根据发表在《Science Direct》杂誌上的一项研究，2025年6月，1,085名住院患者中，16.7%患有细菌感染疾病。

血液感染疾病增加

医院接诊的败血症患者数量激增，这些败血症患者与慢性疾病、侵入性操作以及导管相关感染有关。随着诊断工具日益复杂，早期发现血液中的病原体有助于改善临床疗效。快速分子诊断与基于人工智慧的感染追踪技术的结合正在改变治疗通讯协定。新兴国家正在投资微生物实验室和监测系统，以遏制医院内感染。日益加重的负担正在推动广谱抗生素和特异性病原体的抗生素的创新。

难以取得有效的抗生素

监管障碍和高昂的研发成本阻碍了製药公司开发新型抗生素。许多现有抗生素由于过度使用（尤其是在加护治疗环境中）以及微生物适应性而失效。开发符合全球安全标准并针对多重抗药性细菌的药物的复杂性加剧了这项挑战。规模较小的生物技术公司难以资金筹措临床试验并顺利通过核准途径。如果没有加速创新和全球管理计划，我们的抗生素库存仍然非常有限。

提高早期诊断意识

人们越来越意识到败血症早期诊断的重要性，这为市场拓展开闢了新的途径。医院正在采用就地检验和基于生物标记的筛检，以便及时启动抗生素治疗。基因组定序和人工智慧诊断平台的进步使得快速识别血液中的病原体成为可能。公共卫生宣传活动和临床医生培训计画正在强化早期疗育的价值。政府和非政府组织正在为医疗资源匮乏的地区提供诊断基础设施资金，以降低死亡率。向主动护理的转变正在推动对伴随诊断和客製化抗生素治疗方案的需求。

抗药性患者治疗失败的风险

抗药性患者的治疗失败往往会导致住院时间延长、死亡率上升和医疗费用上升。儘管联合治疗和最后一线抗生素取得了进展，但抗药性机制仍在不断演变。医院已经实施了抗生素管理计划和抗药性监测工具，但不同地区的实施情况存在差异。由于缺乏全抗药性感染疾病的有效替代方案，迫切需要全球合作进行药物研发。如果没有强有力的遏制策略，抗药性败血症可能会阻碍治疗进展。

COVID-19的影响

COVID-19疫情扰乱了抗生素供应链，改变了临床治疗重点，并延误了常规败血症的诊断和治疗。由于医院关闭和生产瓶颈，医院面临关键抗生素和诊断剂的短缺。然而，这场危机加速了远端医疗和远端监控在感染控制的应用。疫情后的策略如今强调分散式照护、抗菌药物管理和人工智慧驱动的感染监测。疫情也凸显了建立韧性供应链和多元化抗生素采购的重要性。

头孢菌素类药物预计将成为预测期内最大的药物

头孢菌素类抗生素因其频谱疗效和良好的安全性，预计在预测期内将占据最大的市场份额。这些抗生素广泛用于血流感染疾病的经验性治疗，尤其是在医院。第三代和第四代头孢菌素的技术进步提高了抗药性覆盖率和药物动力学。医院在等待病原体特异性诊断期间，越来越依赖头孢菌素作为初始治疗。新兴趋势包括复方製剂和缓释性，以提高依从性。持续的技术创新和临床偏好正在巩固头孢菌素在抗生素市场的领先地位。

预测期内，败血性休克领域预计将实现最高复合年增长率

预计在预测期内，败血性休克领域将出现最高成长率，这得益于重症监护病房 (ICU) 入院人数和重症患者介入措施的增加。败血性休克病例需要快速有效的抗生素治疗以及血流动力学支持，因此成为治疗创新的重点。医院正在采用即时监控系统和基于人工智慧的决策支援来管理这些高风险患者。针对产生内毒素的病原体的下一代抗生素的开发正在蓬勃发展。临床试验正在探索免疫调节药物和精准给药演算法等辅助性治疗。人们对败血性休克死亡率的认识不断提高，这加速了对针对性解决方案的投资。

比最大的地区

受医疗基础设施扩张和感染率上升的推动，亚太地区预计将在预测期内占据最大的市场份额。印度、中国和印尼等国家正在投资医院升级和抗菌药物管理计画。政府倡议正在促进国内抗生素生产，并改善诊断的可及性。该地区正在迅速普及数位健康平台和人工智慧驱动的感染监测。全球製药公司与本地製造商之间的策略联盟正在加强市场渗透。

复合年增长率最高的地区：

在强劲的研发投入和先进的医疗体系的推动下，北美预计将在预测期内呈现最高的复合年增长率。美国和加拿大在新型抗生素和快速诊断技术的开发方面处于领先地位。监管机构正在简化针对抗药性败血症菌株的突破性治疗方法的核准流程。医院正在整合物联网驱动的监测和预测分析，以优化抗生素的使用。该地区受益于健全的报销框架和精准医疗的高度普及。随着抗生素抗药性成为国家优先事项，北美将继续推动创新和市场成长。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球败血症抗生素市场（依药物类别）

  • 头孢菌素类
  • 卡巴培南类
  • 糖肽
  • 青霉素
  • Aminoglycosides
  • 其他药物类别

6. 全球败血症抗生素市场（依病原体类型）

  • 细菌
    • 革兰氏阳性
    • 革兰氏阴性
  • 病毒性的
  • 真菌

7. 全球败血症治疗用抗生素市场（依给药途径）

  • 肠外
  • 口服

8. 全球败血症治疗抗生素市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

9. 全球败血症治疗抗生素市场（依应用）

  • 败血症
  • 败血性休克
  • 严重败血症
  • 其他用途

第 10 章。全球败血症治疗抗生素市场（按最终用户）

  • 医院及重症监护室
  • 诊断实验室
  • 专科诊所
  • 其他最终用户

11. 全球败血症治疗抗生素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Pfizer Inc.
  • Endacea Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • GlaxoSmithKline plc（GSK）
  • RegeneRx Biopharmaceuticals Inc.
  • AbbVie Inc.
  • Novartis AG
  • Viatris Inc.
  • AstraZeneca plc
  • Asahi Kasei Corporation
  • Eli Lilly and Company
  • Adrenomed AG
  • Merck & Co., Inc.
  • Inotrem SA
Product Code: SMRC31124

According to Stratistics MRC, the Global Septicemia Antibiotics Market is accounted for $2.73 billion in 2025 and is expected to reach $3.82 billion by 2032 growing at a CAGR of 4.9% during the forecast period. Antibiotics for septicemia are vital drugs prescribed to manage bacterial infections in the bloodstream. Commonly referred to as blood poisoning, septicemia can rapidly become fatal without urgent treatment. These antibiotics act by destroying or inhibiting bacterial growth, helping prevent organ damage and systemic complications. Depending on the infection source, therapy may involve broad-spectrum or pathogen-specific antibiotics, ensuring effective control of the disease. Their use is essential in lowering death rates linked with septicemia.

According to the study published by Science Direct, in June 2025, out of 1,085 hospitalized patients, 16.7% had bacterial infection.

Market Dynamics:

Driver:

Rising prevalence of bloodstream infections

Hospitals are witnessing a surge in septicemia cases linked to chronic illnesses, invasive procedures, and catheter-related infections. As diagnostic tools become more sophisticated, early detection of bloodstream pathogens is improving clinical outcomes. The integration of rapid molecular diagnostics and AI-based infection tracking is transforming treatment protocols. Emerging economies are investing in microbiology labs and surveillance systems to curb hospital-acquired infections. This growing burden is driving innovation in broad-spectrum and pathogen-specific antibiotic formulations.

Restraint:

Limited availability of effective antibiotics

Regulatory hurdles and high R&D costs are discouraging pharmaceutical firms from pursuing new antimicrobial agents. Many existing antibiotics are losing efficacy due to overuse and microbial adaptation, especially in intensive care settings. The complexity of developing drugs that meet global safety standards while targeting multi-drug resistant organisms adds to the challenge. Smaller biotech firms struggle with clinical trial funding and navigating approval pathways. Without accelerated innovation and global stewardship programs, the antibiotic arsenal remains dangerously limited.

Opportunity:

Increasing awareness of early diagnosis

Heightened awareness around the importance of early diagnosis in septicemia is opening new avenues for market expansion. Hospitals are adopting point-of-care testing and biomarker-based screening to initiate timely antibiotic therapy. Advances in genomic sequencing and AI-powered diagnostic platforms are enabling faster identification of bloodstream pathogens. Public health campaigns and clinician training programs are reinforcing the value of early intervention. Governments and NGOs are funding diagnostic infrastructure in underserved regions to reduce mortality rates. This shift toward proactive care is boosting demand for companion diagnostics and tailored antibiotic regimens.

Threat:

Risk of treatment failure in resistant cases

Treatment failure in resistant cases often leads to prolonged hospitalization, increased mortality, and higher healthcare costs. Despite advances in combination therapies and last-resort antibiotics, resistance mechanisms continue to evolve. Hospitals are deploying antimicrobial stewardship programs and resistance monitoring tools, but adoption remains uneven across regions. The lack of effective alternatives for pan-resistant infections is prompting urgent calls for global collaboration in drug development. Without robust containment strategies, resistant septicemia could undermine therapeutic progress.

Covid-19 Impact

The COVID-19 pandemic disrupted antibiotic supply chains and shifted clinical priorities, delaying routine septicemia diagnosis and treatment. Hospitals faced shortages of critical antibiotics and diagnostic reagents due to lockdowns and manufacturing bottlenecks. However, the crisis accelerated adoption of telemedicine and remote monitoring for infection management. \ Post-pandemic strategies now emphasize decentralized care, antimicrobial stewardship, and AI-driven infection surveillance. The pandemic also highlighted the need for resilient supply chains and diversified antibiotic sourcing.

The cephalosporins segment is expected to be the largest during the forecast period

The cephalosporins segment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and favorable safety profile. These antibiotics are widely used in empirical therapy for bloodstream infections, especially in hospital settings. Technological advancements in third- and fourth-generation cephalosporins are enhancing resistance coverage and pharmacokinetics. Hospitals are increasingly relying on cephalosporins for initial treatment while awaiting pathogen-specific diagnostics. Emerging trends include fixed-dose combinations and extended-release formulations to improve compliance. Continuous innovation and clinical preference are reinforcing cephalosporins' leadership in the antibiotic landscape.

The septic shock segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the septic shock segment is predicted to witness the highest growth rate, driven by rising ICU admissions and critical care interventions. Septic shock cases demand rapid, potent antibiotic administration alongside hemodynamic support, making them a priority for therapeutic innovation. Hospitals are adopting real-time monitoring systems and AI-based decision support to manage these high-risk patients. The development of next-gen antibiotics targeting endotoxin-producing pathogens is gaining momentum. Clinical trials are exploring adjunct therapies like immunomodulators and precision dosing algorithms. As awareness of septic shock mortality grows, investment in targeted solutions is accelerating.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by expanding healthcare infrastructure and rising infection rates. Countries like India, China, and Indonesia are investing in hospital upgrades and antimicrobial stewardship programs. Government initiatives are promoting domestic antibiotic production and improving access to diagnostics. The region is witnessing rapid adoption of digital health platforms and AI-driven infection surveillance. Strategic collaborations between global pharma firms and local manufacturers are enhancing market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by strong R&D investment and advanced healthcare systems. The U.S. and Canada are leading in the development of novel antibiotics and rapid diagnostic technologies. Regulatory agencies are streamlining approval processes for breakthrough therapies targeting resistant septicemia strains. Hospitals are integrating IoT-enabled monitoring and predictive analytics to optimize antibiotic use. The region benefits from robust reimbursement frameworks and high adoption of precision medicine. As antimicrobial resistance becomes a national priority, North America continues to drive innovation and market growth.

Key players in the market

Some of the key players profiled in the Septicemia Antibiotics Market include Pfizer Inc., Endacea Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline plc (GSK), RegeneRx Biopharmaceuticals Inc., AbbVie Inc., Novartis AG, Viatris Inc., AstraZeneca plc, Asahi Kasei Corporation, Eli Lilly and Company, Adrenomed AG, Merck & Co., Inc., and Inotrem S.A.

Key Developments:

In September 2025, Johnson & Johnson announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, a novel intravascular lithotripsy (IVL) platform designed to modify calcium in extremely narrowed vessels to expand treatments in patients suffering from peripheral artery disease (PAD).

In July 2025, Pfizer Inc. announced the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company's robust oncology pipeline.

Drug Classes Covered:

  • Cephalosporins
  • Carbapenems
  • Glycopeptides
  • Penicillins
  • Aminoglycosides
  • Other Drug Classes

Pathogen Types Covered:

  • Bacterial
  • Viral
  • Fungal

Route of Administrations Covered:

  • Parenteral
  • Oral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Sepsis
  • Septic Shock
  • Severe Sepsis
  • Other Applications

End Users Covered:

  • Hospitals & ICUs
  • Diagnostic Laboratories
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Septicemia Antibiotics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Cephalosporins
  • 5.3 Carbapenems
  • 5.4 Glycopeptides
  • 5.5 Penicillins
  • 5.6 Aminoglycosides
  • 5.7 Other Drug Classes

6 Global Septicemia Antibiotics Market, By Pathogen Type

  • 6.1 Introduction
  • 6.2 Bacterial
    • 6.2.1 Gram-positive
    • 6.2.2 Gram-negative
  • 6.3 Viral
  • 6.4 Fungal

7 Global Septicemia Antibiotics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Septicemia Antibiotics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Online Pharmacies
  • 8.4 Retail Pharmacies

9 Global Septicemia Antibiotics Market, By Application

  • 9.1 Introduction
  • 9.2 Sepsis
  • 9.3 Septic Shock
  • 9.4 Severe Sepsis
  • 9.5 Other Applications

10 Global Septicemia Antibiotics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & ICUs
  • 10.3 Diagnostic Laboratories
  • 10.4 Specialty Clinics
  • 10.5 Other End Users

11 Global Septicemia Antibiotics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Endacea Inc.
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Johnson & Johnson
  • 13.5 GlaxoSmithKline plc (GSK)
  • 13.6 RegeneRx Biopharmaceuticals Inc.
  • 13.7 AbbVie Inc.
  • 13.8 Novartis AG
  • 13.9 Viatris Inc.
  • 13.10 AstraZeneca plc
  • 13.11 Asahi Kasei Corporation
  • 13.12 Eli Lilly and Company
  • 13.13 Adrenomed AG
  • 13.14 Merck & Co., Inc.
  • 13.15 Inotrem S.A.

List of Tables

  • Table 1 Global Septicemia Antibiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Septicemia Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Septicemia Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
  • Table 4 Global Septicemia Antibiotics Market Outlook, By Carbapenems (2024-2032) ($MN)
  • Table 5 Global Septicemia Antibiotics Market Outlook, By Glycopeptides (2024-2032) ($MN)
  • Table 6 Global Septicemia Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
  • Table 7 Global Septicemia Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
  • Table 8 Global Septicemia Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 9 Global Septicemia Antibiotics Market Outlook, By Pathogen Type (2024-2032) ($MN)
  • Table 10 Global Septicemia Antibiotics Market Outlook, By Bacterial (2024-2032) ($MN)
  • Table 11 Global Septicemia Antibiotics Market Outlook, By Gram-positive (2024-2032) ($MN)
  • Table 12 Global Septicemia Antibiotics Market Outlook, By Gram-negative (2024-2032) ($MN)
  • Table 13 Global Septicemia Antibiotics Market Outlook, By Viral (2024-2032) ($MN)
  • Table 14 Global Septicemia Antibiotics Market Outlook, By Fungal (2024-2032) ($MN)
  • Table 15 Global Septicemia Antibiotics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 16 Global Septicemia Antibiotics Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 17 Global Septicemia Antibiotics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 18 Global Septicemia Antibiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 19 Global Septicemia Antibiotics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 20 Global Septicemia Antibiotics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 21 Global Septicemia Antibiotics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 22 Global Septicemia Antibiotics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Septicemia Antibiotics Market Outlook, By Sepsis (2024-2032) ($MN)
  • Table 24 Global Septicemia Antibiotics Market Outlook, By Septic Shock (2024-2032) ($MN)
  • Table 25 Global Septicemia Antibiotics Market Outlook, By Severe Sepsis (2024-2032) ($MN)
  • Table 26 Global Septicemia Antibiotics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 27 Global Septicemia Antibiotics Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Septicemia Antibiotics Market Outlook, By Hospitals & ICUs (2024-2032) ($MN)
  • Table 29 Global Septicemia Antibiotics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 30 Global Septicemia Antibiotics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 31 Global Septicemia Antibiotics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.